A Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

Trial Profile

A Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Onapristone (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Arno Therapeutics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results (n=36) of an exploratory analysis assessing outcome by plasma androgen receptor (AR) status presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 04 Jan 2017 According to an Arno Therapeutics media release, company has decided not to enroll the remaining 3 patients in the Phase II portion of this trial. 15 patients has been enrolled till date. Company will continue to administered Onapristone to all patients currently enrolled in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top